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Abstract OBJECTIVE: In current literature, the immune-inflammatory theory of athero-
sclerosis is widely discussed. The role of how adhesion molecules contribute to the 
development of atheromatic plaques is especially underlined. 
MATERIAL AND METHODS: 120 females in menopausal age were included in 
the study between 2004 and 2009. All the women were of menopausal age (51±3 
years), from southern Poland, with FSH levels above 30 mIU/ml, and complain-
ing of menopausal symptoms that disturbed normal daily activity. The study 
was conducted over a 6 month period. Three groups of 40 randomized patients 
were selected. The control group consisted of 40 volunteers, who were also from 
southern Poland, in good health, without menopausal symptoms, or menstrual 
periods in the last 6 months. Control subjects were match according to age and 
weight, with FSH levels above 25 mIU/ml and normal TSH and prolactin values. 
All patients, in the treatment and control groups were seronegative for Chlamydia 
pneumonia throughout the duration of the study.
RESULTS: After 6 months, hormonal therapy was found to significantly reduce 
levels of sICAM-1 and sVCAM-1 in all treated groups compared to the control 
group and the results were statistically significant. Alternatively, in the latter 
group, we observed increased levels of the investigated adhesion molecules 
(group I: 37.5 μg/24h transdermal estradiol + dydrogesteron; group II 50 μg/24h 
transdermal estradiol + medroxyprogesteron; group III 1mg of oral estradiol + 
noretisteron sICAM-1 and control group; using paired Wilcoxon test). 
CONCLUSION: All of the investigated estrogen therapy schemas have a favorable 
impact on the blood levels of sICAM-1 and sVCAM-1 in postmenopausal women 
without cardiovascular risk factors, reducing their concentration.
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Abbreviations:
BMI  - body mass index
CAM  - cell adhesion molecules
E2 - estradiol
FSH  - follicle stimulating hormone 
HDL  - high density lipid
hsCRP  - high sensitive C-reactive protein
Ig  - immunoglobulin
IL  - interleukin
LDL  - low density lipid
PRL  - prolactin
sICAM-1  - intercellular adhesion molecule-1 
sVCAM-1  - vascular cell adhesion molecule-1
TNF  - tumor necrosis factor
TSH  - thyroid stimulating hormone
WBC  - leucocytes
WHR  - waist and hipline ratio
 
INTRODUCTION
Certain inflammatory and immune markers in peri- and 
postmenopausal women play an important prognostic 
role in modern medicine. An especially interesting 
issue is the possible impact of postmenopausal declines 
in sex hormone production and medication therapy on 
a vessel’s immune-inflammatory condition (Rossouw 
et al. 2002). Increased levels of inflammatory-immune 
markers are signs of chronic immune-inflammatory 
processes found in: atherosclerosis, arterial hyperten-
sion, obesity, diabetes mellitus, and others.
In current literature, the inflammatory theory of 
atherosclerosis is widely discussed. Markers associated 
with atherosclerotic vascular changes include: high sen-
sitive C-reactive protein (hsCRP), interleukin (IL) 1β, 
IL 6, IL 8, tumor necrosis factor α (TNFα), leucocytes, 
along with cells adhesion molecules (VCAM-1 – vas-
cular cell adhesion molecule-1, ICAM-1 – intercellular 
adhesion molecule-1), fibrinogen, amyloid A protein 
and others. Data demonstrates that circulating inflam-
matory products are chronic bacterial and atheroscle-
rosis markers of inflammation, but furthermore they 
damage epithelium and directly facilitate the develop-
ment of atherosclerosis (Danesh et al.1997; De Backer 
et al. 2002; Dechend et al. 1999).
The role of adhesion molecules in the development 
of the atheromatic plaque is especially emphasized. 
These particles function as intracellular molecules and 
signaling intercellular proteins, and have the ability 
to initiate cytokine secretion and adhesion molecule 
expression in a cell. Cell adhesion molecules (CAMs) 
are involved in a vast away of processes including 
embryonic development, tissue building, inflamma-
tory reactions, wound healing and metastasis. CAMs 
allow cells to interact with their environment and other 
cells; they determine the location of a cell in a tissue or 
organ. Adhesion molecules are divided into several cat-
egories: selectins, integrins, adhesins and a superfam-
ily of immunoglobulins CAM (IgCAM) that includes: 
ICAM-1 and VCAM-1(Ptak & Ptak 1999). These adhe-
sion molecules are released from damaged tissues due 
to shear forces of stress, subsequently reparatible the 
migration of inflammatory cells, within toward the site 
of injury and ultimately triggering the vessel wall. 
Combining knowledge about the beneficial influ-
ence of estrogen on healthy endothelial cells, along with 
the inflammatory theory of atherosclerosis, we col-
lected data which illustrate the influence of three differ-
ent forms estrogen-progestin therapy on the bahaviour 
of serum ICAM-1 and VCAM-1 in healthy postmeno-
pausal women with climacteric symptoms, and com-
pared these results to the control group.
MATERIAL AND METHODS
Series description, inclusion criteria
The study was carried out with 120 women, who had 
been hospitalized or treated in the outpatient clinic at 
the Endocrinological Gynecology Department, at Jagi-
ellonian University, between 2004 and 2009. All patients 
were of menopausal age (51±3 years ), from southern 
Poland, with FSH levels above 30 mIU/ml, and com-
plaining of menopausal symptoms that disturbed their 
normal daily activities. Each patient fulfilled the criteria 
for hormonal therapy as specified by the Standards of 
Polish Gynecological Society. The study was conducted 
over a period of 6 months, during which time no life-
style changes were noted, and investigators observed 
whether quality of life improved (measured by Green 
Scale) and how changed the level of exam markers. No 
other drug use was reported, especially for chronic ill-
nesses. Three groups of 40 randomized patients were 
selected. In the first group we introduced transdermal 
estrogen therapy in a 37.5 μg/24h dose combined with 
a 10 mg dose of dydrogesteron. In the second group we 
introduced transdermal estrogen therapy in a 50 μg/24h 
dose with 2.5 mg of oral medroxyprogesteron. In both 
these groups gestagens were administered continuously. 
In the third group we introduced continuous, oral, low-
dose combined estrogen-gestagen therapy with 1mg of 
ethynyloestradiol and 0.5mg of noretisteron acetate.
Group I (n=20): 37.5 μg/24h of transdermal 
17-β-estradiol, in combination with 10mg of dydroges-
teron (commercial products: Oesclim 37.5 and Duphas-
ton – tablets), abbreviation: 37.5+D
Group II (n=20): 50 μg/24h of transdermal 
17-β-estradiol, in combination with 2.5 mg of medroxy-
progesteron (commercial products: Oesclim 50 and 
Provera 5 mg – half tablet), abbreviation: 50+MPA
Group III (n=20): 1mg of 17-β-estradiol in combi-
nation with 0.5 mg noretisteron acetate as a continuous 
oral therapy (commercial product: Activelle), abbrevia-
tion: Activelle
Selection of above therapy schemas was suitable. 
Cho’s in vivo data has shown that oral gestagen therapy 
enables smooth muscle relaxation by slackening cal-
cium channels, independent of estrogen (Cho 2000). 
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The control group included 40 healthy volunteers 
from southern Poland, without chronic diseases, meno-
pausal symptoms, or menstrual periods in the last 6 
months. These subject were matched for height and 
weight, with FSH levels above 25 mIU/ml and normal 
TSH and prolactin values. All patients, in the treatment 
and control groups, were seronegative for Chlamydia 
pneumonia throughout the duration of the experiment.
Exclusion criteria.
In our study, candidates meeting the following criteria 
were excluded: taking hormone replacement therapy 
at the time of evaluation (medical history), suffering 
form unexplained uterine bleeding, reporting a his-
tory of endometriosis (transvaginal ultrasound), or 
uterine myoma(s), demonstrating arterial hyperten-
sion (daily blood pressure records – systolic pressure 
less then 140 mmHg and diastolic pressure less then 
90 mmHg were accepted as normal), suffering from 
coronary artery disease (echocardiogram, ECG, cardiac 
stress test), serum level of triglycerides greater than 
400 mg/dl, with diabetes mellitus (oral glucose toler-
ance test with 75 g of glucose), with an active or chronic 
inflammatory process (medical history, C-reactive 
protein >10 ng/dl, WBC>10 000/mm3), autoimmune 
diseases, liver dysfunctions (liver function blood tests), 
or kidneys diseases (sodium, potassium, creatinine or 
blood urea level out of norm), reporting neoplasms 
in their medical history, thrombophlebitis or venous 
thromboembolism (medical history), suffered from 
cholelithiasis, but not after cholecystectomy (medical 
history), reporting seizures in the course of a disease 
including epilepsy (medical history), complaining of 
migraine (medical history), overweight or obese (BMI 
score equal to or more than 25 and with waist – hip 
ratio equal to or more than 0.78).
Smoking and alcohol consumption were also taken 
into consideration and excluded the patients from the 
study.
The following tests were performed on each patient:
• a detailed medical history including arte-
rial hypertension, diabetes mellitus, smoking, 
inflammatory conditions, liver and kidneys dis-
eases, neoplasms, and present pharmacological 
treatment 
• physical examination with hemodynamic 
evaluation 
• blood pressure measurement
• anthropometric measurements including body 
weight and height (BMI), and waist and hipline 
ratio (WHR) 
• biochemical tests including morphology, hor-
mone levels (FSH, E2, TSH, PRL), total choles-
terol, LDL-cholesterol, HDL-cholesterol, and 
triglycerides
• serum adhesion molecules level (VCAM-1, 
ICAM-1) 
• IgA antibodies against Chlamydia pneumoniae
All patients were informed about the medical study 
and joined willingly, giving their written consent. Our 
data has agreement from the Ethics Committe of Jagiel-
lonian University.
Serum samples were collected and stored at –70 °C 
degree. All samples were tested at the same time. All 
hormones were determined by immunoassay “ECLIA”. 
Total cholesterol and high density lipoprotein (HDL) 
levels were determined by enzymatic and colorimetric 
methods. Plasma triglyceride levels were determined 
with an enzymatic commercial kit (Abbot). Low den-
sity lipoprotein (LDL) levels were estimated according 
to the Friedwald equation. Serum vascular cell adhe-
sion molecule-1 and serum intercellular adhesion 
molecule-1 were determined by an immunoenzymatic 
method using a commercial kit (R and D System, Eng-
land). IgA antibodies against Chlamydia pneumoniae 
were also examined using an immunoenzymatic 
method (ANI Labsystem, Finland).
Statistial analysis
In the analysis conducted, nonparametric tests were 
used. Analysed parameters in treated groups were 
compared using the Mann-Whitney U test. Using the 
Wilcoxon test, the obtained results in examination 1 
(before administering treatment) and examination 2 
(six months after initiation of hormonal therapy) in 
each study group were compared. The results were ana-
lysed using the Kruskal-Wallis test (ANOVA), and in 
cases where significant changes were found between 
groups, a multiple comparison test was applied to 
detect the differences. R-Pearson’s linear correlation 
ratio was exerted to estimate correlations between 
analyzed parameters and changes in these factors. The 
result p<0.05 was statistically significant. Lack of statis-
tical significance was indicated by the abbreviation NS 
(non-statistically significant).
Results were shown in the form of tables and figures. 
Calculations and analysis were conducted by using 
STATISTICA 7.1.packet.
RESULTS 
Characteristic of the study groups
The women in our study groups do not differ signifi-
cantly based on age, anthropometric measurements, 
hormone levels (E2, FSH, PRL, and TSH), total cho-
lesterol, LDL- and HDL-cholesterol and triglycerides.
There was no statistically significant difference in 
the blood level of VCAM-1 and ICAM-1 in the study 
groups.
The results for the 120 participants in the study and 
control group are shown in Tables 1,2 and Figures 1,2.
The sICAM Kruskal-Wallis test (ANOVA) (Figure 1) 
demonstrated statistically significant differences 
(p<0.001) between changes in results in control and 
study groups. To izolate these differences, a multiple 
comparisons test was performed, subsequently failing 
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In our own data, a linear correlation was dem-
onstrated between changes of sICAM-1, sVCAM-1 
(r=0.6045, p<0.001; r=0.4434, p=0.004) and changes 
of FSH. An inversely proportional correlation between 
changes of sICAM-1, sVCAM-1, and changes of estra-
diol level was also detected (r=–0.64, p<0.001; r=–0.31, 
p=0.049). 
Regression summary for sVCAM-1 and sICAM-1 
reveals further information. A strong proportional cor-
relation exists between adhesive molecules and fibrino-
gen, with estrogen mediating the relationships, despite 
a lack of its exact pathomechanism.
Av inverse correlation exists between sICAM-1, 
sVCAM-1 and antibodies IgA against Chlamydia pneu-
monia, further implicating the proportional depen-
dence of this bacteria on estrogen. Literature has shown 
estrogens ability to stimulate the immune response 
and ward off infections potentially contributing to ath-
erosclerosis. In world literature there are dates which 
present that estrogen may stimulate immune response 
to weak infections that causes that atherosclerosis 
develops slower (Goudev et al. 2002). Our data dem-
onstrated a proportional correlation between estrogen 
and Chlamydia pneumoniae IgA antibodies (higher 
levels of estrogen corresponds higher levels of antibod-
Tab. 1. Level of sICAM-1 in examination 1 (before therapy) and 
examination 2 ( six months after starting hormonal therapy) in 
examined groups.
Study 
groups Test
sICAM-1 (ng/ml)
p-value
x SD min Me max
Activelle 1 266.8 73.3 176.4 277.6 378.0 0.005
2 209.1 67.9 114.2 206.8 322.7
50+MPA 1 256.1 43.3 200.5 244.7 324.1 0.005
2 195.3 40.6 123.1 193.8 260.9
37.5+D 1 280.8 58.6 197.0 272.8 355.1 0.005
2 219.8 50.3 147.2 209.2 300.3
Control 
group
1 305.8 67.3 190.6 301.5 387.9 0.009
2 391.3 58.6 312.6 382.9 499.4
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Tab. 2. Level of sVCAM-1 in examination 1 (before therapy) and 
examination 2 (six months after starting hormonal therapy) in 
examined groups.
Study 
groups Test
sVCAM-1 (ng/ml)
p-value
x SD min Me max
Activelle 1 599.2 199.2 254.8 555.3 987.5 0.005
2 535.1 193.0 200.7 497.7 902.1
50+MPA 1 669.7 108.0 587.3 632.1 953.8 0.05
2 575.1 94.6 499.0 539.0 812.2
37.5+D 1 718.9 164.2 499.1 734.7 932.1 0.007
2 590.9 154.5 409.5 526.5 855.2
Control 
group
1 688.6 159.9 499.2 678.5 987.3 0.05
2 836.1 162.2 576.8 854.7 1099.5
Fig. 1. Comparison of changes in levels of sICAM-1 between study 
groups in examined population.
Fig. 2. The comparison of changes in levels of sVCAM-1 between 
study groups in examined population.
to detect any statistically significant differences. Clini-
cally, this indicates that each dose of estrogen, made of 
administration, and type of oral gestagen has a positive 
effect on sICAM-1 levels. Analogical observation was 
done due to sVCAM-1 (Figure 2), but no statistically 
significant differences were detected in the control 
group after six months.
DISCUSSION
In current literature, the beneficial influence of hor-
monal therapy on bahaviour of sICAM-1 and sVCAM-1 
is widely discussed.
The pathomechanism of this observation is still 
unclear, but there are many suggestions, including the 
theory that estrogen represses the expression of adhe-
sion molecules’ genes (Goudev et al. 2002; Lamon-Fava 
et al. 2003; Mueck et al. 2007; Ridker et al. 1998; Shifren 
et al. 2008). In our study, we proved that there is a bene-
ficial effect on sICAM-1 and sVCAM-1 after hormonal 
treatment, as compared to the control group. However, 
we would like to emphasize that there is no statistically 
significant difference between the discussed groups, 
according to dose of estrogen, made of administration , 
or the type of gestagen given.
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ies of Chlamydia pneumonia which are still seronega-
tive). It is worth noting that although increased level 
of antibodies IgA class of Chlamydia pneumoniae were 
observed, the results were negative for the entire dura-
tion of the experiment.
In conclusion, each of the investigated estrogen ther-
apy schemas had a favorable impact on the blood level 
of sICAM-1 and sVCAM-1 in postmenopausal women 
without cardiovascular risk factors. The study strongly 
underline that estrogen application healthy women 
aged 50–59 prolong their life in good condition what is 
the main device of antiaging medicine. 
An essential element in the prevention of endothelial 
dysfunction is to identify new biochemical or immuno-
logical markers including adhesive molecules. Adhesive 
molecules are markers of the formation and progres-
sion of endothelial dysfunction, but their clinical role 
warrants further investigation.
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